Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

NCT03887455 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT03887455
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03887455 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
Lead sponsor
Eisai Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 27, 2019
Completion date
December 31, 2026
Enrollment
1,906 (actual)
Sites
247

Conditions

As the registry lists them; a condition with its own page is linked.

early alzheimer's disease